A recent study using rodent models of hypertension and heart failure demonstrated that the systemic subcutaneous administration of an α‐CGRP analogue (an acylated form of α‐CGRP with extended half‐life, t1/2 = ~7h) reversed the renal, vascular, and cardiac damage caused by angiotensin II‐induced hypertension or by abdominal aortic constriction (AAC)‐induced heart failure (Aubdool et al. 2017). Here, CALCA is linked to heart failure.